Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Collier

Showing results (341-350 of 508) with videos related to

Pageof 51
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 24, 2011
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRTHeather J Ribaudo, Constance A Benson, Yu Zheng, et al.
Chemphyschem : a European Journal of Chemical Physics and Physical Chemistry|December 6, 2002
Two-dimensional molecular electronics circuitsYi Luo, Patrick C Collier, Jan O Jeppesen, et al.
Journal of Acquired Immune Deficiency Syndromes|February 1, 1994
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3M A Fischl, L Resnick, R Coombs, et al.
Brain, Behavior, & Immunity - Health|March 21, 2022
Peripheral inflammation and depressed mood independently predict neurocognitive worsening over 12 yearsRonald J Ellis, Robert K Heaton, Bin Tang, et al.
Annals of Internal Medicine|May 15, 1990
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials GroupM A Fischl, D D Richman, N Hansen, et al.
AIDS (London, England)|July 1, 1995
The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudineM A Jacobson, V De Gruttola, M Reddy, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 11, 2015
Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging StudyLi Liu, Ann C Collier, Jeanne M Link, et al.
AIDS (London, England)|July 14, 2011
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapyRonald J Ellis, Jayraan Badiee, Florin Vaida, et al.
Annals of Neurology|April 1, 1993
Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials GroupJ J Sidtis, C Gatsonis, R W Price, et al.
AIDS (London, England)|January 26, 2005
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 resultsAngela Dm Kashuba, Camlin Tierney, Gerald F Downey, et al.
Pageof 51

Showing results (341-350 of 508) with videos related to

Sort By:
Pageof 51
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 24, 2011
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRTHeather J Ribaudo, Constance A Benson, Yu Zheng, et al.
Chemphyschem : a European Journal of Chemical Physics and Physical Chemistry|December 6, 2002
Two-dimensional molecular electronics circuitsYi Luo, Patrick C Collier, Jan O Jeppesen, et al.
Journal of Acquired Immune Deficiency Syndromes|February 1, 1994
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3M A Fischl, L Resnick, R Coombs, et al.
Brain, Behavior, & Immunity - Health|March 21, 2022
Peripheral inflammation and depressed mood independently predict neurocognitive worsening over 12 yearsRonald J Ellis, Robert K Heaton, Bin Tang, et al.
Annals of Internal Medicine|May 15, 1990
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials GroupM A Fischl, D D Richman, N Hansen, et al.
AIDS (London, England)|July 1, 1995
The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudineM A Jacobson, V De Gruttola, M Reddy, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 11, 2015
Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging StudyLi Liu, Ann C Collier, Jeanne M Link, et al.
AIDS (London, England)|July 14, 2011
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapyRonald J Ellis, Jayraan Badiee, Florin Vaida, et al.
Annals of Neurology|April 1, 1993
Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials GroupJ J Sidtis, C Gatsonis, R W Price, et al.
AIDS (London, England)|January 26, 2005
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 resultsAngela Dm Kashuba, Camlin Tierney, Gerald F Downey, et al.
Pageof 51